chr3-136256588-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000532.5(PCCB):c.337C>T(p.Arg113Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000459 in 1,613,130 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000532.5 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PCCB | NM_000532.5 | c.337C>T | p.Arg113Ter | stop_gained | 3/15 | ENST00000251654.9 | NP_000523.2 | |
PCCB | NM_001178014.2 | c.337C>T | p.Arg113Ter | stop_gained | 3/16 | NP_001171485.1 | ||
PCCB | XM_011512873.2 | c.337C>T | p.Arg113Ter | stop_gained | 3/11 | XP_011511175.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PCCB | ENST00000251654.9 | c.337C>T | p.Arg113Ter | stop_gained | 3/15 | 1 | NM_000532.5 | ENSP00000251654 | P2 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152030Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000318 AC: 8AN: 251476Hom.: 0 AF XY: 0.0000368 AC XY: 5AN XY: 135912
GnomAD4 exome AF: 0.0000479 AC: 70AN: 1460982Hom.: 0 Cov.: 29 AF XY: 0.0000509 AC XY: 37AN XY: 726882
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152148Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74370
ClinVar
Submissions by phenotype
Propionic acidemia Pathogenic:11
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 08, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 07, 2019 | Variant summary: PCCB c.337C>T (p.Arg113X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 2.8e-05 in 246256 control chromosomes (gnomAD). c.337C>T has been reported in the literature in multiple individuals affected with Propionic Acidemia (Brosch_2008, Cheng_2017, Kraus_2012, Sanchez-Alcudia_2012). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function (Kraus_2012, Sanchez-Alcudia_2012). The most pronounced variant effect results in <10% of normal activity. Three ClinVar submissions from clinical diagnostic laboratories (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Feb 23, 2023 | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.003%). This variant was predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. The variant has been reported at least twice as pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000265422 / PMID: 17415538). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 30, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Dec 08, 2015 | The p.Arg113X variant in PCCB has been reported in one individual with propionic acidemia (Brosch 2008) and has been identified in 3/66722 of European chromosom es by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; db SNP rs186031457). This nonsense variant leads to a premature termination codon a t position 113, which is predicted to lead to a truncated or absent protein. Los s of function of the PCCB gene is an established disease mechanism in individual s with propionic acidemia. In summary, this variant meets our criteria to be cla ssified as pathogenic for propionic acidemia in an autosomal recessive manner ba sed upon its predicted impact on protein function. - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Laboratory Sciences Program (CLSP), King Saud bin Abdulaziz University for Health Sciences (KSAU-HS) | Apr 01, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Jan 08, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 25, 2023 | This sequence change creates a premature translational stop signal (p.Arg113*) in the PCCB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PCCB are known to be pathogenic (PMID: 15464417). This variant is present in population databases (rs186031457, gnomAD 0.01%). This premature translational stop signal has been observed in individuals with propionic acidemia (PMID: 22033733). ClinVar contains an entry for this variant (Variation ID: 265422). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | DASA | Apr 10, 2022 | The c.337C>T;p.(Arg113*) variant creates a premature translational stop signal in the PCCB gene. It is expected to result in an absent or disrupted protein product -PVS1. This sequence change has been observed in affected individual(s) and ClinVar contains an entry for this variant (ClinVar ID: 265422; PMID: 17415538; 22334403; 22033733; 30705822; 31916709) - PS4. The variant is present at low allele frequencies population databases (rs186031457 – gnomAD 0.0002631%; ABraOM no frequency - https://abraom.ib.usp.br/) - PM2_supporting. The p.(Arg113*) was detected in trans with a pathogenic variant (PMID: 17415538; 22033733; 31916709). PM3. In summary, the currently available evidence indicates that the variant is pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genomic Research Center, Shahid Beheshti University of Medical Sciences | May 03, 2020 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 12, 2023 | Functional studies of this variant found that it results in a truncated protein (Snchez-Alcudia et al. 2012); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 30609409, 25525159, 17415538, 22033733, 33981581, 22334403) - |
Abnormality of metabolism/homeostasis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Kariminejad - Najmabadi Pathology & Genetics Center | Jul 10, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at